Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNA001 in Postoperative Differentiated Thyroid Cancer for Diagnostic Support
CTR20260588Phase 3Active
- Sponsor
- SmartNuclide
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human thyroid-stimulating hormone beta in well-differentiated thyroid cancer (WDTC), sponsored by SmartNuclide. Started May 2026; status: active.
02
Drugs
recombinant human thyroid-stimulating hormone beta
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20260588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260588.